Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Muckenhirn Keith E

2. Date of Event Requiring Statement (MM/DD/YYYY) 9/4/2016

3. Issuer Name and Ticker or Trading Symbol

ANTARES PHARMA, INC. [ATRS]

(Last) (First) (Middle)

C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
VP/Controller & Interim CFO /

(Street)

EWING, NJ 08628

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	50000	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	1/16/2010 ⁽¹⁾	1/15/2017	Common Stock $0.01 par value per share	30000	$1.23	D
Stock Option (right to buy)	5/10/2010 ⁽¹⁾	5/9/2017	Common Stock $0.01 par value per share	15000	$1.65	D
Stock Option (right to buy)	5/14/2011 ⁽¹⁾	5/13/2018	Common Stock $0.01 par value per share	45000	$0.85	D
Stock Option (right to buy)	11/12/2011 ⁽¹⁾	11/11/2018	Common Stock $0.01 par value per share	20000	$0.47	D
Stock Option (right to buy)	11/11/2012 ⁽¹⁾	11/11/2019	Common Stock $0.01 par value per share	45000	$1.10	D
Stock Option (right to buy)	11/11/2013 ⁽¹⁾	11/10/2020	Common Stock $0.01 par value per share	35000	$1.52	D
Stock Option (right to buy)	5/17/2015 ⁽¹⁾	5/16/2022	Common Stock $0.01 par value per share	20000	$2.94	D
Stock Option (right to buy)	5/22/2016 ⁽¹⁾	5/22/2023	Common Stock $0.01 par value per share	30000	$3.96	D
Stock Option (right to buy)	⁽²⁾	11/19/2024	Common Stock $0.01 par value per share	35000	$2.29	D
Stock Option (right to buy)	⁽³⁾	5/29/2024	Common Stock $0.01 par value per share	35000	$3.09	D
Stock Option (right to buy)	⁽⁴⁾	5/28/2025	Common Stock $0.01 par value per share	35000	$2.18	D
Stock Option (right to buy)	⁽⁵⁾	6/2/2026	Common Stock $0.01 par value per share	40000	$1.12	D

Explanation of Responses:
( 1)	Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options vested in equal quarterly installments over three years from the initial grant date. The exercisable date listed above represents the date the options became fully vested and exercisable.
( 2)	Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on November 20, 2014 and are vesting in equal quarterly installments over three years from the initial grant date.
( 3)	Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on May 29, 2014 and are vesting in equal quarterly installments over three years from the initial grant date.
( 4)	Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on May 28, 2015 and are vesting in equal quarterly installments over three years from the initial grant date.
( 5)	Represents grant of options to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. The options were granted on June 2, 2016 and are vesting in equal quarterly installments over three years from the initial grant date.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Muckenhirn Keith E C/O ANTARES PHARMA, INC. 100 PRINCETON SOUTH, SUITE 300 EWING, NJ 08628			VP/Controller & Interim CFO

Signatures
Keith Muckenhirn		9/12/2016
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.